The purpose behind the Molecular Diagnostics Market Report is to outline the condition of the market of Molecular Diagnostics, to show real data about the volumes of interest, pattern, industry size and the condition of the market, the progressions that occurred in 2018, and furthermore.
— Molecular diagnostic tests are highly useful in detecting certain sequences in DNA or RNA, which include single nucleotide polymorphism (SNP), rearrangements, deletions, insertions, as well as others so the disease can be further diagnosed. Such cumulative techniques are used for the analyzation of biological markers at the molecular level, like proteome and genome. Furthermore, such techniques can also be used for diagnosing various infectious diseases, cancer, along with many other conditions, in addition to checking the genetic predisposition to a disease.
The growth of in-vitro diagnostics is expected to reinforce the growth of the molecular diagnostic market. Reports that appraise the medical device industry have been presented by Market Research Future, which creates reports on industry verticals that assess the market development and prospects. The market is anticipated to gain a CAGR of 9.6 % in the forecast period.
The rising preference for early treatment and diagnosis of diseases is anticipated to motivate the molecular diagnostic market. The soaring rates of infectious diseases are expected to create a favorable growth momentum for the molecular diagnostics globally. Moreover, the rise of unhealthy lifestyles is projected to create promising options for development in the forecast period.
Get Free Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/1171
Key players for Global Molecular Diagnostics Market
Several companies in the molecular diagnostics market are looking to collaborate with research institutes in order to advance their own product development programs. Recently, EZLife announced a collaboration with the UCLA to expand EGFR lung cancer assay into RUO offerings. Such collaborations are likely to be common among key players in the molecular diagnostics market.
The top vendors in the Global Molecular Diagnostics Market include Hologic, Inc. (U.S.), QIAGEN N.V. (the Netherlands), Grifols (Spain), Bio-Rad Laboratories, Inc. (US), Abbott (U.S.), Siemens Healthcare GmbH (Germany), F. Hoffmann-La Roche Ltd. (U.S.), Cepheid (U.S.), BD (U.S.), bioMérieux SA (France), Beckman Coulter Inc. (U.S.), and others.
Molecular Diagnostics Market - Overview
Molecular diagnostics is a branch of diagnostics which utilizes molecular biology to detect and measure the presence of genetic material or proteins related to a specific health condition. Molecular diagnostics is the fastest growing branch in vitro diagnosis as it has been able to achieve highest diagnosis accuracy and enables early diagnosis and prevention of diseases. The global molecular diagnostics market is expected to grow remarkably as it possesses the ability to conduct genetic tests that were previously not possible and it has the potential to replace the present microbiological and clinical methods of diagnosis. Market Research Future (MRFR), asserts that the global molecular diagnostics market is set to capture a CAGR of 9.6 % during the forecast period (2018-2023).
The relentlessly expanding geriatric population around the world is expected to render tremendous positive impact on the growth of the molecular diagnostics market over the given timeframe. This is true as aging radically augments the risk of infectious and chronic conditions which can be taken care of better when diagnosed at an initial stage of development. Also, United Nations forecasts that the global geriatric population is set to expand from the value of 962 million in 2017 to 2.1 billion by the year 2050. This drastic increase in the elderly population base coupled with the consequent surge in demand for early and improved diagnostic methods will be highly instrumental in the growth of the molecular diagnostics market in the near future.
February 2019 – Co-Diagnostics, Inc. has recently launched its first multi-disease diagnostic which was built by using their patented CoPrimer design platform. This diagnostic test can be used for dengue, chikungunya and Zika, which was developed to cater to the market demand for a cost-effective and highly-accurate diagnostic tool for all the three diseases.
Myriad Genetics, Inc., a leading company pioneering molecular diagnostics has announced seven new payer coverage decisions for Prolaris, a standard 46-gene RNA-expression test for detection and measurement of prostate cancer. 25 leading insurer in the U.S. are included in the payers.
The evaluation of the segments in the molecular diagnostics market is conducted on the basis of techniques, region, applications, and end users. On the basis of techniques, the molecular diagnostics market is segmented into transcription-mediated amplification, fluorescence in-situ hybridization, PCR (Polymerase Chain Reaction) and real-time PCR, microarray, and next-generation sequencing. Based on the applications, the molecular diagnostics market is segmented into oncology, blood screening, infectious diseases, genetic testing, human leukocyte antigen typing, pharmacogenomics, coagulation, and others. The end user-based segmentation of the molecular diagnostics market comprises of diagnostic laboratories, hospitals, academics, and research institutions. On the basis of regions, the molecular diagnostics market consists of the Americas, Europe, the Middle East, Asia Pacific, and Africa.
Study of the regions in the molecular diagnostics market comprises of the Americas, Europe, the Middle East, Asia Pacific, and Africa. The Americas region controls the global market for molecular diagnostics owing to the growing demand for progressive techniques and increased spending on the life science domain are the key factors for the development of the Americas market. Additionally, owing to the presence of well-developed technology, a growing patient pool with bone disorders, increased healthcare expenditure, and rising government support for research & development. The European region records the next chief market share trailed by the Asia Pacific region. Intensifying prevalence of lifestyle and chronic diseases, an escalating number of private diagnostic centers are the chief factors accountable for the progress of the market. Furthermore, soaring demand for quality devices in the healthcare sector is anticipated to guide the use of advanced equipment, which will increase the market progress of molecular diagnostics in the region. Conversely, blood disorders in the Middle East and Africa have become an enormous issue due to restricted screening, unawareness of diseases, and restricted access to treatment
Some Brief Table of Contents of Report
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope Of The Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
Browse Complete Report @ https://www.marketresearchfuture.com/reports/molecular-diagnostics-market-1171
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Name: Market Research Future
Email: Send Email
Organization: Market Research Future
Address: Office No. 528, Amanora Chambers, Magarpatta Road, Hadapsar, Pune – 411028, Maharashtra, India
Phone: +1 646 845 9312
Release ID: 88909826